EPOPROSTENOL
epoprostenol 500 microgram injection, 1 vial
EPOPROSTENOL (10130E)
10130E
Body System:
Manner of administration:Injection
Restriction
Indication: Pulmonary arterial hypertension (PAH)
Treatment phase: Initial 1 (new patients)
Restriction
Indication: Pulmonary arterial hypertension (PAH)
Treatment phase: Initial 2 (change)
Restriction
Indication: Pulmonary arterial hypertension (PAH)
Treatment phase: Continuing treatment
Restriction
Indication: Pulmonary arterial hypertension (PAH)
Treatment phase: Initial 1 - starting combination therapy (dual or triple therapy, excluding selexipag)
in an untreated patient
Restriction
Indication: Pulmonary arterial hypertension (PAH)
Treatment phase: Initial 2 - starting combination therapy (dual or triple therapy, excluding selexipag)
in a treated patient where a diagnosis of pulmonary arterial hypertension is established
through a prior PBS authority application
Restriction
Indication: Pulmonary arterial hypertension (PAH)
Treatment phase: Initial 3 - changing to this drug in combination therapy (dual or triple therapy)
Restriction
Indication: Pulmonary arterial hypertension (PAH)
Treatment phase: Continuing treatment of combination therapy (dual or triple therapy, excluding selexipag)
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 30 | Max qty units: 30 | # of repeats: 5 | DPMQ: $998.40 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Veletri | |||||